73
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      The Clinical Utility of miR-21 and let-7 in Non-small Cell Lung Cancer (NSCLC). A Systematic Review and Meta-Analysis

      systematic-review

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Non-small cell lung cancer (NSCLC) remains a problem worldwide due to its rapid progression and low rate of response to treatment. The heterogeneity of these tumors observed in histopathology exam but also in the mutational status and gene expression pattern makes this malignancy difficult to treat in clinic. The present study investigated the effect of miR-21 and let-7 family members as prognostic biomarkers in NSCLC patients based on the results published in different studies regarding this subject until March 2019. The analysis revealed that these two transcripts are steady biomarkers for prediction of patient outcome or survival. Upregulated expression of miR-21 is associated with poor outcome of patients with NSCLC [HR = 1.87, 95% CI = (1.41, 2.47), p < 0.001]. The analysis regarding let-7 family, specifically let-7a/b/e/f, revealed that downregulated expression of these transcripts predicts poor outcome for NSCLC patients [HR = 2.61, 95% CI = (1.58, 4.30), p < 0.001]. Besides, the reliability of these microRNAs is reflected in the fact that their prognostic significance is constant given the different sample types (tissue, FFPE tissue, serum, serum/plasma or exosomes) used in the selected studies.

          Related collections

          Most cited references77

          • Record: found
          • Abstract: found
          • Article: not found

          Global Cancer Statistics 2018: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries

          This article provides a status report on the global burden of cancer worldwide using the GLOBOCAN 2018 estimates of cancer incidence and mortality produced by the International Agency for Research on Cancer, with a focus on geographic variability across 20 world regions. There will be an estimated 18.1 million new cancer cases (17.0 million excluding nonmelanoma skin cancer) and 9.6 million cancer deaths (9.5 million excluding nonmelanoma skin cancer) in 2018. In both sexes combined, lung cancer is the most commonly diagnosed cancer (11.6% of the total cases) and the leading cause of cancer death (18.4% of the total cancer deaths), closely followed by female breast cancer (11.6%), prostate cancer (7.1%), and colorectal cancer (6.1%) for incidence and colorectal cancer (9.2%), stomach cancer (8.2%), and liver cancer (8.2%) for mortality. Lung cancer is the most frequent cancer and the leading cause of cancer death among males, followed by prostate and colorectal cancer (for incidence) and liver and stomach cancer (for mortality). Among females, breast cancer is the most commonly diagnosed cancer and the leading cause of cancer death, followed by colorectal and lung cancer (for incidence), and vice versa (for mortality); cervical cancer ranks fourth for both incidence and mortality. The most frequently diagnosed cancer and the leading cause of cancer death, however, substantially vary across countries and within each country depending on the degree of economic development and associated social and life style factors. It is noteworthy that high-quality cancer registry data, the basis for planning and implementing evidence-based cancer control programs, are not available in most low- and middle-income countries. The Global Initiative for Cancer Registry Development is an international partnership that supports better estimation, as well as the collection and use of local data, to prioritize and evaluate national cancer control efforts. CA: A Cancer Journal for Clinicians 2018;0:1-31. © 2018 American Cancer Society.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            MicroRNAs: genomics, biogenesis, mechanism, and function.

            MicroRNAs (miRNAs) are endogenous approximately 22 nt RNAs that can play important regulatory roles in animals and plants by targeting mRNAs for cleavage or translational repression. Although they escaped notice until relatively recently, miRNAs comprise one of the more abundant classes of gene regulatory molecules in multicellular organisms and likely influence the output of many protein-coding genes.
              Bookmark
              • Record: found
              • Abstract: not found
              • Article: not found

              Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement.

                Bookmark

                Author and article information

                Contributors
                Journal
                Front Oncol
                Front Oncol
                Front. Oncol.
                Frontiers in Oncology
                Frontiers Media S.A.
                2234-943X
                19 October 2020
                2020
                : 10
                : 516850
                Affiliations
                [1] 1Research Center for Functional Genomics, Biomedicine and Translational Medicine, “Iuliu-Hatieganu” University of Medicine and Pharmacy Cluj-Napoca , Cluj-Napoca, Romania
                [2] 2Department of Psychology, Babes-Bolyai University , Cluj-Napoca, Romania
                [3] 3Research Center for Advanced Medicine MedFuture, “Iuliu Hatieganu” University of Medicine and Pharmacy Cluj-Napoca , Cluj-Napoca, Romania
                [4] 4Pathology Unit, Department of Experimental, Diagnostic and Specialty Medicine, DIMES, University of Bologna , Bologna, Italy
                [5] 5Department of Functional Genomics and Experimental Pathology, The Oncology Institute “Prof. Dr. Ion Chiricută” , Cluj-Napoca, Romania
                Author notes

                Edited by: Rengyun Liu, The First Affiliated Hospital of Sun Yat-sen University, China

                Reviewed by: Vincenzo Graziano, University of Cambridge, United Kingdom; Simone Anfossi, University of Texas MD Anderson Cancer Center, United States

                *Correspondence: Ioana Berindan-Neagoe ioana.neagoe@ 123456umfcluj.ro

                This article was submitted to Cancer Genetics, a section of the journal Frontiers in Oncology

                †These authors have contributed equally to this work

                Article
                10.3389/fonc.2020.516850
                7604406
                33194579
                63297052-818e-4f81-88b8-e715d1af9810
                Copyright © 2020 Pop-Bica, Pintea, Magdo, Cojocneanu, Gulei, Ferracin and Berindan-Neagoe.

                This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

                History
                : 08 January 2020
                : 21 September 2020
                Page count
                Figures: 6, Tables: 3, Equations: 0, References: 77, Pages: 14, Words: 8769
                Categories
                Oncology
                Systematic Review

                Oncology & Radiotherapy
                prognostic,biomarker,nsclc,mir-21,let-7,patients
                Oncology & Radiotherapy
                prognostic, biomarker, nsclc, mir-21, let-7, patients

                Comments

                Comment on this article